- A director at Sensus Healthcare, Inc. recently purchased 1,500 shares, signaling confidence in the company’s future.
- The company experienced a revenue decline in Q1 2026, primarily due to the absence of a major customer and the transition to new CPT codes for Superficial Radiotherapy (SRT).
- Despite revenue challenges, Sensus Healthcare, Inc. reports positive initial results from the new CPT codes and has resolved a commercial dispute, allowing for strategic refocus.
Sensus Healthcare, Inc. (NASDAQ:SRTS) is a leading medical device company that focuses on advanced treatments for non-melanoma skin cancer. The company specializes in developing and selling Superficial Radiotherapy (SRT) systems. These innovative devices provide a crucial non-surgical alternative for patients, utilizing low-energy radiotherapy to effectively treat various skin conditions.
A significant event highlighting investor confidence is recent insider activity. On May 12, 2026, director Sachetta Eric purchased 1,500 shares of Sensus Healthcare, Inc.’s stock at a price of $3.34 per share. Following this strategic director stock purchase, his total holdings in Sensus Healthcare, Inc. now stand at 143,613 shares.
This notable insider activity occurs as Sensus Healthcare, Inc. navigates a period of significant change within the medical device market. The company’s first-quarter 2026 revenue was $3.40 million, marking a decrease from $8.30 million reported in the same quarter of 2025. As highlighted by Business Wire, this revenue decline is primarily attributed to the absence of sales to its largest historical customer.
This strategic shift is largely driven by the introduction of new dedicated CPT codes for SRT, which became effective on January 1, 2026. CPT codes are essential for medical professionals to accurately bill insurance for procedures. As highlighted by MarketBeat, Sensus Healthcare, Inc. dedicated the quarter to educating its customers on this critical new reimbursement structure, adapting to evolving healthcare policy changes.
Despite the recent revenue decline, Sensus Healthcare, Inc. maintains a positive outlook, observing encouraging signs. Chairman Joe Sardano describes the initial results from the new CPT codes as “excellent,” indicating that customers are successfully receiving payments. Furthermore, Sensus Healthcare, Inc. reached an “amicable resolution” to a commercial dispute with SkinCure Oncology, which allows the company to effectively refocus on its strategy and capitalize on potential SRT market growth.
